Dissociation between beta-2 microglobulin and IL-1 production in hemodialyzed patients

Carreno, Marie‐Paule; Rousseau, Yanaelle; Poignet, J. L.; Jahns, G; Cholley, Béatrice; Kazatchkine, M. D.; Haeffner‐Cavaillon, Nicole

doi:10.1093/ndt/12.11.2365

Cited by 8 publications

(8 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The association of inflammatory biomarkers and β 2 M has been the focus of many studies during the 1990s before the development of modern synthetic dialyzers (17, 212–215). This partially contradictory literature suggests an association between inflammation, triggered by membrane material, and serum β 2 M concentrations.…”

Section: β2m In Esrdmentioning

confidence: 99%

Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases

et al. 2017

View full text Add to dashboard Cite

There is currently an unmet need for better biomarkers across the spectrum of renal diseases. In this paper, we revisit the role of beta-2 microglobulin (β2M) as a biomarker in patients with chronic kidney disease and end-stage renal disease. Prior to reviewing the numerous clinical studies in the area, we describe the basic biology of β2M, focusing in particular on its role in maintaining the serum albumin levels and reclaiming the albumin in tubular fluid through the actions of the neonatal Fc receptor. Disorders of abnormal β2M function arise as a result of altered binding of β2M to its protein cofactors and the clinical manifestations are exemplified by rare human genetic conditions and mice knockouts. We highlight the utility of β2M as a predictor of renal function and clinical outcomes in recent large database studies against predictions made by recently developed whole body population kinetic models. Furthermore, we discuss recent animal data suggesting that contrary to textbook dogma urinary β2M may be a marker for glomerular rather than tubular pathology. We review the existing literature about β2M as a biomarker in patients receiving renal replacement therapy, with particular emphasis on large outcome trials. We note emerging proteomic data suggesting that β2M is a promising marker of chronic allograft nephropathy. Finally, we present data about the role of β2M as a biomarker in a number of non-renal diseases. The goal of this comprehensive review is to direct attention to the multifaceted role of β2M as a biomarker, and its exciting biology in order to propose the next steps required to bring this recently rediscovered biomarker into the twenty-first century.

show abstract

Section: β2m In Esrdmentioning

confidence: 99%

Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases

et al. 2017

View full text Add to dashboard Cite

show abstract

“…This would also support clinical observations that the quality of the water is more important for the plasma ␤ 2 -microglobulin concentrations than the type of dialyzer membrane used [8,21] . Moreover, Carreno et al [22] found a dissociation between ␤ 2 -microglobulin and interleukin-1 production in hemodialyzed patients suggesting that stimulated ␤ 2 -microglobulin synthesis does not contribute to increased plasma levels.…”

Section: Discussionmentioning

confidence: 99%

Increased Binding of Beta-2-Microglobulin to Blood Cells in Dialysis Patients Treated with High-Flux Dialyzers Compared with Low-Flux Membranes Contributed to Reduced Beta-2-Microglobulin Concentrations

Traut¹,

Haufe

Eismann³

et al. 2007

Blood Purif

View full text Add to dashboard Cite

Background: Patients on long-term dialysis eventually develop amyloid deposits with β₂-microglobulin as a predominant component. Although several studies have suggested that high-flux membranes reduce β₂-microglobulin in plasma compared with low-flux dialyzers, the mechanisms underlying this observation are still discussed. Methods: We revisited this important subject and measured β₂-microglobulin in the plasma of healthy individuals (n = 8), and patients undergoing hemodialysis (n = 20) who for assigned periods of time were either treated with a low-flux membrane (cuprophan) or high-flux (polyamide) dialyzer with an ELISA. The number of blood cells was determined by FACS. β₂-Microglobulin was also measured on the surface of granulocytes, lymphocytes, and monocytes before, directly after, and 4 h after hemodialysis. Expression of β₂-microglobulin, c-fos, tumor necrosis factor-α (TNF-α), and interleukin-1 mRNA was determined in whole blood samples with quantitative RT-PCR using an internal standard in parallel. In the second part of the study, patients were assigned in a two-group cross-over design either to low- or high-flux dialyzers (n = 9 in each group), and dialyzer membranes were changed every 4 weeks for two consecutive periods. Serum β₂-microglobulin concentrations were measured at the end of each period. Results: Healthy controls had a low plasma β₂-microglobulin level of 1.2 ± 0.3 mg/l. Before hemodialysis, patients on low-flux dialyzers had a plasma β₂-microglobulin level of 42.0 ± 14.0 mg/l, patients treated with high-flux dialyzers 21.5 ± 10.8 mg/l (p < 0.05 vs. low-flux dialyzers). In contrast, there was no significant difference in plasma concentrations of active transforming growth factor-β1 with the two different membrane types. The difference in serum β₂-microglobulin between low- and high-flux membranes was more prominent directly after hemodialysis as well as 4 h after hemodialysis compared with the values directly before the start of treatment. At all studied time-points, leukocytes and platelets were significantly higher in patients on low-flux membranes. Healthy control persons exhibited a significantly higher amount of β₂-microglobulin bound to granulocytes, lymphocytes, and monocytes compared with dialysis patients. Interestingly, β₂-microglobulin bound to granulocytes, lymphocytes, and monocytes was significantly increased in patients treated with high-flux membranes compared with low-flux filters. Quantitative RT-PCR revealed no significant difference in β₂-microglobulin expression in whole blood before hemodialysis, directly after hemodialysis, and 4 h after hemodialysis. However, TNF-α and c-fos transcripts were significantly higher in whole blood obtained from patients treated with low-flux membranes compared to high-flux dialyzers. The two-group cross-over study over three periods of 4 weeks revealed that switching from low-flux to high-flux dialyzers si...

show abstract

“…It was observed that theses inflammatory cytokines, especially IL-6 play a role in regulation of β2M gene expression in human hepatoma cells, Tcells, T-lymphocytes, and monocytes (13). Therefore, it can be said that changes in proinflammatory cytokines and, in this context, changes in nutritional parameters can be associated with changes in β2M concentration.…”

Section: Figmentioning

confidence: 99%

“…In a study by Carreno et al, it was indicated that proinflammatory cytokines, such as IL-1, TNF-α, and IL-6 play a key role in the pathogenesis of increased serum β2M in hemodialysis patients (13). It was observed that theses inflammatory cytokines, especially IL-6 play a role in regulation of β2M gene expression in human hepatoma cells, Tcells, T-lymphocytes, and monocytes (13).…”

Section: Figmentioning

confidence: 99%

An Investigation of the Relationship between Beta-2 Microglobulin (β2M) and Inflammatory Factors (Serum Levels of CRP and Albumin) and High Density Lipoproteins (HDL) in Hemodialysis Patients

et al. 2018

View full text Add to dashboard Cite

Background and Objective: Beta-2 Microglobulin (β2M) is a middle molecular weight uremic toxin. Lack of β2M removal leads to β2M accumulation and amyloidosis in hemodialysis patients. The present research aims to determine the relationship between β2M and inflammatory factors, such as C-reactive protein (CRP), albumin, and high-density lipoprotein (HDL) in hemodialysis patients.Methods: Fifty-four hemodialysis patients were selected and their pre-and post-dialysis serum levels of β2M, CRP, albumin, and HDL, were measured.Result: There was an obvious inverse relationship between β2M level and serum level of albumin, while no relationship was found between β2M and CRP or HDL.Conclusion: According to the findings of this study, it was identified that inflammatory-induced increase in β2M level in dialysis patients leads to reduced serum albumin.

show abstract

Dissociation between beta-2 microglobulin and IL-1 production in hemodialyzed patients

Abstract: Our data indicated that chronic inflammation, as demonstrated by increased intracellular IL-1 expression, is not associated with increased production of beta-2 microglobulin by monocytes from patients on hemodialysis.

Cited by 8 publications

References 9 publications

Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases

Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases

Increased Binding of Beta-2-Microglobulin to Blood Cells in Dialysis Patients Treated with High-Flux Dialyzers Compared with Low-Flux Membranes Contributed to Reduced Beta-2-Microglobulin Concentrations

An Investigation of the Relationship between Beta-2 Microglobulin (β2M) and Inflammatory Factors (Serum Levels of CRP and Albumin) and High Density Lipoproteins (HDL) in Hemodialysis Patients

Contact Info

Product

Resources

About